An increasing body of evidence has demonstrated that RUNX2 is aberrantly overexpressed in numerous cancer tissues including pancreatic cancer relative to their corresponding normal ones, and its depletion suppresses their malignant phenotypes such as migration, invasion, metastasis and drug resistance. This evidence concerns the gene RUNX2 and familial pancreatic carcinoma.